RCKT

Rocket Pharmaceuticals Inc

2.54

Oct 29 • 3:59 PM ET -0.04 (-1.55%)

2.54

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: LXEO TNYA RGNX SLDB SRPT FDMT ABEO QURE MGTX BEAM

| Held by: VTI IWM VXF FESM IWN IBB VTWO DFAS SCHA PRFZ

Scroll to Statements

Index	RUT
Market Cap	278.83M
Enterprise Value	19.88M
Income	-17.25M
Sales	0.00M
Book/sh	3.37
Cash/sh	2.58
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	202
IPO	Feb 18, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.75
P/C	0.98
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.24
Current Ratio	9.24
Debt/Eq	0.07
LT Debt/Eq	0.06
Option/Short	Yes / Yes

EPS (ttm)	-0.18
EPS next Y	-1.36
EPS next Q	-0.40
EPS this Y	93.53%
EPS next Y	-948.43%
EPS next 5Y	18.58%
EPS past 3/5Y	14.88% 4.46%
Sales past 3/5Y	- -
EPS Y/Y TTM	93.45%
Sales Y/Y TTM	-
EPS Q/Q	273.32%
Sales Q/Q	-
Earnings	Aug 10 AMC
EPS/Sales Surpr.	25.58% -100.00%

Insider Own	5.57%
Insider Trans	-3.32%
Inst Own	91.67%
Inst Trans	1.20%
ROA	-4.09%
ROE	-4.77%
ROIC	-4.42%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	5.54%
SMA50	-14.90%
SMA200	-26.56%
Trades

Shs Outstand	109.54M
Shs Float	103.66M
Short Float	15.71%
Short Ratio	8.95
Short Interest	16.28M
52W High	5.45 -53.39%
52W Low	2.16 17.32%
Volatility	7.58% 7.51%
ATR (14)	0.19
RSI (14)	48.86
Beta	0.50
Rel Volume	1.01
Avg Volume	1.82M
Volume	1,829,557

Perf Week	9.96%
Perf Month	-3.42%
Perf Quarter	-18.33%
Perf Half Y	-27.01%
Perf YTD	-27.64%
Perf Year	-32.80%
Perf 3Y	-85.69%
Perf 5Y	-91.45%
Perf 10Y	-91.12%
Recom	2.14
Target Price	8.58
Prev Close	2.58
Price	2.54
Change %	-1.55%

Consensus

Buy

Avg. Price Target

$8.58

Implied Upside

+237.8%

Analysts14incl. previous ratings

Rating Distribution7 Buy · 6 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 08, 2026	Upgrade	GGoldman	Sell → Neutral	$4	+57.5%
Sep 16, 2026	Upgrade	NNeedham	Hold → Buy	$9	+254.3%
Sep 01, 2026	Resumed	CChardan Capital Markets	Buy	$11	+333.1%
Nov 18, 2025	Downgrade	JJP Morgan	Neutral → Underweight
Aug 20, 2025	Upgrade	BBofA Securities	Neutral → Buy	$10	+293.7%
Jul 25, 2025	Downgrade	BBofA Securities	Buy → Neutral	$4	+57.5%
May 30, 2025	Downgrade	EEvercore ISI	Outperform → In-line	$5	+96.9%
May 28, 2025	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$7	+175.6%
May 28, 2025	Downgrade	LLeerink Partners	Outperform → Market Perform	$8	+215.0%
May 28, 2025	Downgrade	JJP Morgan	Overweight → Neutral
May 28, 2025	Downgrade	JJefferies	Buy → Hold	$2.50	-1.6%
May 28, 2025	Downgrade	GGoldman	Neutral → Sell	$2	-21.3%
May 27, 2025	Downgrade	TTD Cowen	Buy → Hold
May 27, 2025	Downgrade	NNeedham	Buy → Hold
Mar 12, 2025	Initiated	BBMO Capital Markets	Outperform	$50	+1,868.5%
Dec 30, 2024	Initiated	WWedbush	Outperform	$32	+1,159.8%
Dec 18, 2024	Initiated	JJefferies	Buy	$29	+1,041.7%
Oct 16, 2024	Initiated	BScotiabank	Sector Outperform
Apr 02, 2024	Initiated	GGoldman	Neutral	$39	+1,435.4%
Oct 24, 2023	Initiated	CCantor Fitzgerald	Overweight	$65	+2,459.1%

Oct-15-26 07:00AM	Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference (Business Wire) +6.79%
Oct-07-26 11:36AM	Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility (Proactive)
09:36AM	Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar (Business Wire)
07:10AM	MARKETS LIVE: Wall Street ends lower as 30-year Treasury yield hits 2002 high (Proactive)
06:42AM	Rocket receives $150m credit facility to advance cardiovascular portfolio (Pharmaceutical Technology)
04:12PM	Loading…
Oct-06-26 04:12PM	Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital (Business Wire)
Sep-18-26 06:24AM	Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug (BioPharma Dive)
Sep-16-26 09:42AM	Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls (The Fly)
08:07AM	Rocket Pharmaceuticals FDA Decision Clears Meaningful Regulatory Overhang, Says Needham Sees 150% Upside Potential In RCKT Stock (Stocktwits)
Sep-15-26 10:21AM	Rocket Pharmaceuticals Shares Rise 8% After FDA Alignment on Danon Disease Trial (InvestorsHub)
10:12AM	Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights (Stocktwits)
07:00AM	Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease (Business Wire)
Sep-03-26 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-10-26 06:15PM	Rocket Pharmaceuticals: Q2 Earnings Snapshot (Associated Press)
04:00PM	Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress (Business Wire)
07:00AM	Loading…
Aug-03-26 07:00AM	Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease (Business Wire) +9.65%
Jun-12-26 07:00AM	Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million (Business Wire)
May-28-26 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-07-26 04:08PM	Rocket Pharmaceuticals: Q1 Earnings Snapshot (Associated Press)
04:00PM	Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress (Business Wire)
Apr-29-26 05:34AM	Rocket to sell PRV for $180m to advance gene therapy pipeline (Hospital Management)
Apr-28-26 07:00AM	Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher (Business Wire)
Mar-27-26 02:48PM	Nasdaq slides into correction amid Iran tensions and oil surge (Proactive) -19.62%
09:56AM	Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI (Proactive)
07:00AM	Rocket Pharmaceuticals Announces FDA Approval of KRESLADI for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire)
Mar-03-26 01:15PM	Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances (Proactive)
Feb-27-26 12:46PM	RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus (Zacks) +10.60%
Feb-26-26 04:04PM	Rocket Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress (Business Wire)
Feb-23-26 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire) +5.56%
07:44PM	Loading…
Feb-18-26 07:44PM	Morgan Stanley Names Rocket Pharmaceuticals (RCKT) as Key Beneficiary of 2026 Biotech Sector Recovery (Insider Monkey) +8.41%
Jan-05-26 07:00AM	Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-15-25 11:10PM	Rocket Pharmaceuticals (RCKT) Stock Target Reduced Following Q3 2025 Update on Cash Position (Insider Monkey)
Dec-09-25 11:57AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Nov-25-25 07:00AM	Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference (Business Wire)
Nov-18-25 09:41AM	Amazon downgraded, Alphabet upgraded: Wall Street's top analyst calls (The Fly)
Nov-06-25 04:09PM	Rocket Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire)
Oct-26-25 06:43AM	Is Rocket Pharmaceuticals (RCKT) One of the Best NASDAQ Stocks Under $5 to Buy Now? (Insider Monkey)
Oct-15-25 11:31AM	RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy (Zacks)
Oct-14-25 07:00AM	Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire) +23.05%
Oct-10-25 04:00PM	Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.81%
Oct-03-25 11:33AM	Rocket ditches blood disorder gene therapy in ongoing pipeline pivot (Pharmaceutical Technology)
Aug-28-25 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-21-25 11:13AM	RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study (Zacks)
07:10AM	Rocket to relaunch rare disease trial after FDA approval (Clinical Trials Arena)
Aug-20-25 11:02AM	Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. (Barrons.com) +28.87%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:00AM	Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease (Business Wire)
06:46AM	Rocket can resume gene therapy trial after FDA lifts hold (BioPharma Dive)
Aug-19-25 12:09AM	Jefferies Raises PT on Rocket Pharmaceuticals, Inc. (RCKT) to $3.00; Maintains 'Hold' Rating (Insider Monkey)
Aug-17-25 11:41PM	Rocket Pharmaceuticals Reorganizes, Cuts Workforce by 30% to Focus on AAV Cardiovascular Platform (Insider Monkey)
Aug-07-25 04:07PM	Rocket Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance) -7.44%
04:00PM	Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire)
Aug-06-25 04:24PM	Did You Lose Money on Rocket Pharmaceuticals, Inc. (RCKT)? Levi & Korsinsky Urges Investors to Act Before August 11, 2025 (Newsfile)
Aug-05-25 08:45AM	Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
Jul-30-25 04:37PM	Investors in Rocket Pharmaceuticals, Inc. (RCKT): Protect Your Rights - Contact Levi & Korsinsky Before August 11, 2025 (Newsfile)
01:14PM	Top FDA Official's Surprise Departure Means More Uncertainty for Biotech (Barrons.com)
Jul-29-25 08:45AM	Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
Jul-24-25 07:00AM	Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs (Business Wire)
06:55AM	Rocket lays off staff; Abivax capitalizes on immune drug data (BioPharma Dive)
Jul-18-25 11:28AM	RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure (Zacks) -8.98%
Jul-17-25 07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy (Business Wire) +16.78%
Jul-15-25 08:58AM	Rocket Pharmaceuticals Receives FDA IND Clearance for BAG3-DCM Gene Therapy RP-A701 (Insider Monkey) -7.87%
Jul-10-25 09:55AM	Danon Disease Treatment Modality Market Analysis and Forecasts 2025-2035 \| Next-Gen Sequencing Speeds Up Danon Disease Diagnosis and Treatment Pathways (GlobeNewswire)
Jul-01-25 11:55AM	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks) +5.71%
09:00AM	Investors in Rocket Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
07:25AM	Rocket Pharmaceuticals receives FDA clearance of RP-A701 (TipRanks)
Jun-30-25 07:00AM	Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy (Business Wire)
Jun-20-25 11:27AM	Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street. (Barrons.com)
09:00AM	Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
Jun-19-25 03:00AM	Gene Therapy Has Lost Support on Wall Street. There's Still Hope for Big Cures. (Barrons.com)
May-28-25 06:00PM	Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow (Insider Monkey) +6.44% +5.65%
01:20PM	William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback (Insider Monkey)
11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
May-27-25 08:01PM	Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death (Insider Monkey) -62.84%
11:50AM	Top Stock Movers Now: Tesla, AutoZone, Newmont, and More (Investopedia)
11:35AM	Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies (Investopedia)
10:37AM	CoreWeave, Rocket Pharmaceuticals, SoundHound: Trending Tickers (Yahoo Finance Video)
07:00AM	Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease (Business Wire)
May-15-25 03:15PM	Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy (Business Wire) +11.07%
May-13-25 08:54AM	Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now? (Insider Monkey) -5.50%
May-09-25 04:30PM	Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy (Business Wire)
10:41AM	RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
May-08-25 04:01PM	Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire) +5.07%
Apr-16-25 11:59AM	Big banks report Q1 beats, China stops taking Boeing deliveries: Morning Buzz (TipRanks) -5.82%
Apr-10-25 11:16AM	Rocket Pharma Out Of Orbit, But Ready For Relaunch (Seeking Alpha) -8.52%
Apr-09-25 10:55AM	Rocket Pharmaceuticals (RCKT): Among Stocks Under $10 that Will Triple (Insider Monkey) +12.73%
Apr-03-25 07:00AM	Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference (Business Wire) -11.75%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -12.89%
Mar-26-25 10:40AM	Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now? (InsiderMonkey) -5.88%
Feb-27-25 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress (Business Wire)
Jan-02-25 04:00PM	Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-24 08:05AM	Wedbush starts Rocket Pharmaceuticals with Outperform into inflection year (TipRanks)
Dec-18-24 02:16PM	Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy' (Investopedia)
Dec-11-24 07:00AM	Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
Dec-10-24 04:01PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-26-24 07:00AM	Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference (Business Wire)
Nov-18-24 11:00AM	Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference (Business Wire)
Nov-12-24 04:01PM	Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Associations 2024 Late-Breaking Science Sessions (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wilson Martin	General Counsel	Sep 11 '26	Sale	3.40	75,364	256,464	598,489	Sep 15 08:27 PM
Militello John	Former Officer	Sep 15 '26	Proposed Sale	3.30	6,897	22,730		Sep 15 04:50 PM
Militello John	Former Officer	Sep 14 '26	Proposed Sale	3.32	6,857	22,731		Sep 14 03:25 PM
Wilson Martin	Officer	Sep 11 '26	Proposed Sale	3.40	75,364	256,486		Sep 11 04:57 PM
Militello John	Former Officer	Sep 11 '26	Proposed Sale	3.40	8,923	30,368		Sep 11 04:55 PM
Wilson Martin	General Counsel	Aug 18 '26	Sale	3.38	631	2,133	673,853	Aug 20 05:30 PM
Shah Gaurav	CEO	Aug 18 '26	Sale	3.38	2,293	7,753	1,056,594	Aug 20 05:25 PM
Shah Gaurav	Officer	Aug 18 '26	Proposed Sale	3.38	2,293	7,754		Aug 18 03:49 PM
Wilson Martin	Officer	Aug 18 '26	Proposed Sale	3.38	631	2,134		Aug 18 03:47 PM
Militello John	Former Officer	Aug 18 '26	Proposed Sale	3.38	1,252	4,234		Aug 18 03:43 PM
Shah Gaurav	CEO	Aug 13 '26	Sale	3.38	2,837	9,592	1,058,887	Aug 17 05:52 PM
Wilson Martin	General Counsel	Aug 13 '26	Sale	3.38	3,493	11,810	674,484	Aug 17 05:50 PM
Stevens Christopher James	Chief Operating Officer	Aug 11 '26	Sale	3.50	36,658	128,266	505,784	Aug 13 04:15 PM
Chaudhuri Sarbani	See Remarks	Aug 11 '26	Sale	3.50	4,701	16,449	262,809	Aug 13 04:15 PM
Wilson Martin	Officer	Aug 13 '26	Proposed Sale	3.38	3,493	11,810		Aug 13 04:03 PM
Shah Gaurav	Officer	Aug 13 '26	Proposed Sale	3.38	2,837	9,592		Aug 13 03:39 PM
Stevens Christopher James	Officer	Aug 11 '26	Proposed Sale	3.50	36,658	128,281		Aug 11 03:30 PM
Chaudhuri Sarbani	Officer	Aug 11 '26	Proposed Sale	3.50	4,701	16,451		Aug 11 03:23 PM
Malik Fady Ibraham	Director	Jul 07 '26	Proposed Sale	3.88	10,670	41,393		Jul 07 03:13 PM
Shah Gaurav	CEO	May 21 '26	Option Exercise	1.69	76,490	129,345	1,117,408	May 26 07:47 PM
Shah Gaurav	CEO	May 21 '26	Sale	3.09	55,684	171,841	1,061,724	May 26 07:47 PM
Shah Gaurav	CEO	May 19 '26	Sale	3.01	2,409	7,261	1,040,918	May 21 04:06 PM
Wilson Martin	General Counsel	May 19 '26	Sale	3.01	662	1,995	677,977	May 21 04:06 PM
Militello John	See Remarks	May 19 '26	Sale	3.01	384	1,157	89,780	May 21 04:06 PM
Shah Gaurav	Officer	May 21 '26	Proposed Sale	3.09	55,684	171,821		May 21 03:40 PM
Shah Gaurav	Officer	May 19 '26	Proposed Sale	3.01	2,409	7,262		May 19 03:38 PM
Militello John	Officer	May 19 '26	Proposed Sale	3.01	384	1,158		May 19 03:33 PM
Wilson Martin	Officer	May 19 '26	Proposed Sale	3.01	662	1,996		May 19 03:20 PM
Wilson Martin	General Counsel	May 13 '26	Sale	3.61	3,361	12,120	678,639	May 14 04:22 PM
Shah Gaurav	CEO	May 13 '26	Sale	3.61	2,728	9,837	1,043,327	May 14 04:19 PM
Militello John	See Remarks	May 13 '26	Sale	3.61	855	3,083	90,164	May 14 04:16 PM
Wilson Martin	Officer	May 13 '26	Proposed Sale	3.61	3,361	12,118		May 13 03:15 PM
Shah Gaurav	Officer	May 13 '26	Proposed Sale	3.61	2,728	9,836		May 13 03:13 PM
Militello John	Officer	May 13 '26	Proposed Sale	3.61	855	3,083		May 13 03:10 PM
Chaudhuri Sarbani	See Remarks	May 07 '26	Sale	3.84	17,650	67,741	267,510	May 11 07:48 PM
Chaudhuri Sarbani	Officer	May 07 '26	Proposed Sale	3.84	17,650	67,741		May 07 03:14 PM
Militello John	See Remarks	Feb 18 '26	Sale	3.34	1,157	3,862	91,019	Feb 20 04:31 PM
Shah Gaurav	CEO	Feb 18 '26	Sale	3.34	5,990	19,995	1,046,055	Feb 20 04:26 PM
Wilson Martin	General Counsel	Feb 18 '26	Sale	3.34	1,376	4,593	682,000	Feb 20 04:09 PM
Wilson Martin	General Counsel	Feb 13 '26	Sale	3.31	12,253	40,582	683,376	Feb 18 05:42 PM
Militello John	See Remarks	Feb 13 '26	Sale	3.31	3,726	12,341	92,176	Feb 18 05:38 PM
Shah Gaurav	CEO	Feb 13 '26	Sale	3.31	12,279	40,668	1,052,045	Feb 18 05:33 PM
Militello John	Officer	Feb 18 '26	Proposed Sale	3.34	1,157	3,863		Feb 18 04:58 PM
Wilson Martin	Officer	Feb 18 '26	Proposed Sale	3.34	1,376	4,594		Feb 18 04:50 PM
Shah Gaurav	Officer	Feb 18 '26	Proposed Sale	3.34	5,990	19,998		Feb 18 04:50 PM
Wilson Martin	Officer	Feb 13 '26	Proposed Sale	3.31	12,253	40,583		Feb 13 04:31 PM
Shah Gaurav	Officer	Feb 13 '26	Proposed Sale	3.31	12,279	40,669		Feb 13 03:55 PM
Schwartz Jonathan David	Officer	Feb 13 '26	Proposed Sale	3.31	14,508	48,052		Feb 13 03:53 PM
Militello John	Officer	Feb 13 '26	Proposed Sale	3.31	3,726	12,341		Feb 13 03:39 PM
Bjork Elisabeth	Director	Jan 02 '26	Buy	3.44	10,000	34,400	50,000	Jan 06 04:05 PM
Schwartz Jonathan David	See Remarks	Nov 18 '25	Sale	2.98	2,545	7,592	299,064	Nov 20 04:05 PM
Shah Gaurav	CEO	Nov 18 '25	Sale	2.98	6,276	18,721	778,296	Nov 20 04:05 PM
Militello John	See Remarks	Nov 18 '25	Sale	2.98	1,086	3,240	65,920	Nov 20 04:05 PM
Wilson Martin	General Counsel	Nov 18 '25	Sale	2.98	1,646	4,910	383,816	Nov 20 04:05 PM
Schwartz Jonathan David	Officer	Nov 18 '25	Proposed Sale	2.98	2,545	7,591		Nov 18 03:57 PM
Shah Gaurav	Officer	Nov 18 '25	Proposed Sale	2.98	6,276	18,720		Nov 18 03:26 PM
Militello John	Officer	Nov 18 '25	Proposed Sale	2.98	1,086	3,239		Nov 18 03:16 PM
Wilson Martin	Officer	Nov 18 '25	Proposed Sale	2.98	1,646	4,910		Nov 18 03:16 PM

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The firm's multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

CEO & DirectorDr. Gaurav D. Shah M.D.

Gen. CounselMr. Martin Louis Wilson J.D.

Chief Operating OfficerMr. Christopher Stevens

Principal Accounting OfficerMr. Joseph Manhede

Chief Science & Gene Therapy OfficerDr. Jonathan Schwartz M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RCKT

Rocket Pharmaceuticals Inc

Upgrade your Finviz experience